RBC Capital Reiterates Outperform on Caribou Biosciences, Maintains $14 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Luca Issi has reiterated an Outperform rating on Caribou Biosciences (NASDAQ:CRBU) and maintained a $14 price target.
August 07, 2024 | 3:53 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital analyst Luca Issi has reiterated an Outperform rating on Caribou Biosciences and maintained a $14 price target.
The reiteration of an Outperform rating and the maintenance of a $14 price target by RBC Capital is a positive signal for investors, suggesting confidence in the company's future performance. This is likely to have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100